Display options
Cite
Izumiya Y, Araki S, Usuku H, et al. Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling. Int J Vasc Med. 2012;2012:246058doi: 10.1155/2012/246058.
Izumiya, Y., Araki, S., Usuku, H., Rokutanda, T., Hanatani, S., & Ogawa, H. (2012). Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling. International journal of vascular medicine, 2012246058. https://doi.org/10.1155/2012/246058
Izumiya, Yasuhiro, et al. "Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling." International journal of vascular medicine vol. 2012 (2012): 246058. doi: https://doi.org/10.1155/2012/246058
Izumiya Y, Araki S, Usuku H, Rokutanda T, Hanatani S, Ogawa H. Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling. Int J Vasc Med. 2012;2012:246058. doi: 10.1155/2012/246058. Epub 2012 Jul 17. PMID: 22848833; PMCID: PMC3405723.
Copy Download .nbib Format: NLM
Share it on

Int J Vasc Med. 2012;2012:246058. doi: 10.1155/2012/246058. Epub 2012 Jul 17.

Chronic C-Type Natriuretic Peptide Infusion Attenuates Angiotensin II-Induced Myocardial Superoxide Production and Cardiac Remodeling.

International journal of vascular medicine

Yasuhiro Izumiya, Satoshi Araki, Hiroki Usuku, Taku Rokutanda, Shinsuke Hanatani, Hisao Ogawa

Affiliations

  1. Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860-8556, Japan.

PMID: 22848833 PMCID: PMC3405723 DOI: 10.1155/2012/246058

Abstract

Myocardial oxidative stress and inflammation are key mechanisms in cardiovascular remodeling. C-type natriuretic peptide (CNP) is an endothelium-derived cardioprotective factor, although its effect on cardiac superoxide generation has not been investigated in vivo. This study tested the hypothesis that suppression of superoxide production contributes to the cardioprotective action of CNP. Angiotensin II (Ang II) or saline was continuously infused subcutaneously into mice using an osmotic minipump. Simultaneously with the initiation of Ang II treatment, mice were infused with CNP (0.05 μg/kg/min) or vehicle for 2 weeks. The heart weight to tibial length ratio was significantly increased by Ang II in vehicle-treated mice. Treatment with CNP decreased Ang II-induced cardiac hypertrophy without affecting systolic blood pressure. Echocardiography showed that CNP attenuated Ang II-induced increase in wall thickness, left ventricular dilatation, and decrease in fractional shortening. CNP reduced Ang II-induced increases in cardiomyocyte size and interstitial fibrosis and suppressed hypertrophic- and fibrosis-related gene expression. Finally, CNP decreased Ang II-induced cardiac superoxide production. These changes were accompanied by suppression of NOX4 gene expression. Our data indicate that treatment with CNP attenuated Ang II-induced cardiac hypertrophy, fibrosis, and contractile dysfunction which were accompanied by reduced cardiac superoxide production.

References

  1. J Mol Med (Berl). 2007 Aug;85(8):797-810 - PubMed
  2. Endocrinology. 2004 May;145(5):2131-40 - PubMed
  3. Hypertension. 2008 Feb;51(2):296-301 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2008 May;28(5):863-70 - PubMed
  5. Circ Res. 2003 Oct 31;93(9):802-5 - PubMed
  6. Circ Res. 2002 Jun 14;90(11):1205-13 - PubMed
  7. Cardiovasc Res. 2003 Feb;57(2):515-22 - PubMed
  8. Eur J Heart Fail. 2005 Dec;7(7):1145-8 - PubMed
  9. Circ Res. 2005 Apr 29;96(8):838-46 - PubMed
  10. J Mol Cell Cardiol. 2008 Feb;44(2):336-44 - PubMed
  11. Pharmacol Rev. 2000 Mar;52(1):11-34 - PubMed
  12. Am Heart J. 1991 Apr;121(4 Pt 1):1244-63 - PubMed
  13. Circulation. 1998 Aug 25;98(8):794-9 - PubMed
  14. Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H984-93 - PubMed
  15. Eur J Vasc Endovasc Surg. 2012 Jun;43(6):649-54 - PubMed
  16. J Am Coll Cardiol. 2008 Jul 1;52(1):60-8 - PubMed
  17. J Am Coll Cardiol. 2005 Feb 15;45(4):608-16 - PubMed
  18. Hypertension. 2007 Feb;49(2):241-8 - PubMed
  19. Circ J. 2007 Jul;71(7):1040-6 - PubMed
  20. Circulation. 2004 Mar 9;109(9):1168-71 - PubMed
  21. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):548-57 - PubMed
  22. J Biol Chem. 2005 Jun 17;280(24):23041-7 - PubMed
  23. Circulation. 2002 Jan 29;105(4):509-15 - PubMed
  24. Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4735-40 - PubMed
  25. Circ Res. 2003 Oct 31;93(9):874-83 - PubMed
  26. Circulation. 2003 Feb 4;107(4):571-3 - PubMed
  27. Hypertens Res. 2008 Feb;31(2):325-34 - PubMed
  28. Biochem Biophys Res Commun. 2007 Apr 27;356(1):60-6 - PubMed
  29. J Clin Invest. 1992 Sep;90(3):1145-9 - PubMed
  30. Cardiovasc Res. 2006 Feb 1;69(2):318-28 - PubMed
  31. Lancet. 2007 Oct 27;370(9597):1483-93 - PubMed
  32. Cardiovasc Res. 2006 Oct 1;72(1):112-23 - PubMed
  33. Endocr Rev. 2006 Feb;27(1):47-72 - PubMed
  34. Nat Med. 2004 Dec;10(12):1384-9 - PubMed
  35. Endocrinology. 2003 Jun;144(6):2279-84 - PubMed
  36. Physiol Genomics. 2006 Aug 16;26(3):180-91 - PubMed

Publication Types